Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Lantheus Holdings's Sloan Ratio for the quarter that ended in Mar. 2026 was 17.42%.
As of Mar. 2026, Lantheus Holdings has a Sloan Ratio of 17.42%, indicating there is a warning stage of accrual build up.
Lantheus Holdings (NAS:LNTH) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Lantheus Holdings has a Sloan Ratio of 17.42%, indicating there is a warning stage of accrual build up.
Lantheus Holdings Sloan Ratio % Related Terms
Lantheus Holdings Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNTH vs HIMS, LQDA, AMRX: Sloan Ratio % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Sloan Ratio % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Lantheus Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Lantheus Holdings's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was 78.755 (Jun. 2025 ) + 27.771 (Sep. 2025 ) + 54.088 (Dec. 2025 ) + 118.417 (Mar. 2026 ) = $279 Mil.
Lantheus Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 87.106 (Jun. 2025 ) + 105.294 (Sep. 2025 ) + 90.178 (Dec. 2025 ) + 125.127 (Mar. 2026 ) = $408 Mil.
Lantheus Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -232.472 (Jun. 2025 ) + -319.468 (Sep. 2025 ) + -11.51 (Dec. 2025 ) + 25.986 (Mar. 2026 ) = $-537 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Sloan Ratio % of 17.42% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Lantheus Holdings and its competitors.
Is Lantheus Holdings' Sloan Ratio % too high?
Lantheus Holdings' current Sloan Ratio % is 17.42%. Overall, Lantheus Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Sloan Ratio % compare to HIMS and LQDA?
Lantheus Holdings' Sloan Ratio % of 17.42% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Drug Manufacturers company?
A good Sloan Ratio % depends on the Drug Manufacturers industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Lantheus Holdings and its competitors. Lantheus Holdings's current Sloan Ratio % is 17.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Fairly Valued. The stock's GF Value™ is $90.49, compared to a current price of $99.57 — trading 10% above its estimated fair value. The current Sloan Ratio % is 17.42%. Lantheus Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Sloan Ratio % is 17.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $99.57 is trading 10% above its estimated GF Value™ of $90.49.
GuruFocus considers Lantheus Holdings to be Fairly Valued.
Key valuation signals for LNTH:
Sloan Ratio %: 17.42%
GF Value™: $90.49 vs. price of $99.57 (10% above fair value)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score
Get the complete analysis for LNTH
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
